Tests imatinib before surgery in adults with triple negative breast cancer
Tests imatinib tablets before surgery in adults with triple negative breast cancer.
Plain-language title generated from the registry record
Registry title: Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
Key facts
- Where
- Gothenburg, SwedenSee the site
Where in Sweden
- Barbro LinderholmGothenburg, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vastra Gotaland Region
- Trial code
- NCT05722795
- Record updated
- 9 July 2025
- Original description
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option.Read full original descriptionShow less
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15 mm, any status in the axilla when neoadjuvant treatment not is considered as an option.
The primary aim is to determine the proportion of patients that converts to estrogen receptor (ER) positive breast cancer in the removed breast cancer tissue at surgery.
Inclusion: Histological confirmed invasive primary triple negative breast cancer≥15 mm) with any node status; Age ≥18 years; Triple Negative subtype is defined below:; Hormone receptor status: the invasive tumour shall be ER- and progesterone receptor (PR) -negative [staining present in <10% by immunohistochemistry (IHC)]; HER2 status: the invasive tumour shall be Human Epidermal growth factor Receptor (HER) 2-negative by the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines; No previous systemic treatment for TNBC; No concurrent anti-cancer treatment. Treatment with Bisphosphonates may continue; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Normal organ function as defined below:; absolute white blood cell count ≥1.5 x 109/L; platelets ≥100 x 109/L; haemoglobin ≥90g/dL; total bilirubin ≤1.5 x institutional upper normal limit (UNL)/dL (≤ 3 x UNL for patients with Gilbert´s syndrome); ASAT, ALAT, GGT and alkaline phosphatase levels < 1.5 × institutional UNL; albumin >2.5mg/dL; Creatinine < 110 μmol/L; T3, T4 and TSH (only patients with previous thyroid dysfunction); Patients of childbearing potential must have a negative serum or urine pregnancy test within 8 days prior to start of imatinib treatment; Female patients of childbearing potential must agree to usecontraceptive methods with a failure rate below 1% per year during the study treatment and at least 90 days after the last dose of imatinib; Patients must be able to take (swallow) an oral medication; Patients must be capable to understand and comply with the protocol and has signed the informed consent.
Exclusion: Concomitant treatment for breast cancer within 14 days before registration; Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ); Known human immunodeficiency virus (HIV) positivity; Known active Hepatitis B or Hepatitis C; Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance; Patients suitable for neoadjuvant treatment; Unable to adhere to the study procedures; Pregnancy and breast-feeding.